Clinical trial
Randomized, Double-blind, Safety and Efficacy of Recombinant Human Erythropoietin in Amyotrophic Lateral Sclerosis
NCT03835507 is registered in ClinicalTrials.gov with Hanyang University Seoul Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized, Double-blind, Safety and Efficacy of Recombinant Human Erythropoietin in Amyotrophic Lateral Sclerosis
- Lead sponsor
- Hanyang University Seoul Hospital
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- June 20, 2016
- Completion date
- December 31, 2025
- Enrollment
- 64 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.